AAV CDMO

Our AAV CDMO service supports biopharmaceutical companies throughout the entire gene therapy lifecycle. We provide comprehensive process and analytical development, scalable upstream and downstream manufacturing, and QC testing under GMP standards. Each AAV project benefits from personalized attention, transparent communication, and a robust technical framework designed for efficiency and compliance.

As an AAV gene therapy CDMO, 3PBIOVIAN specializes in the development and production of AAV vectors used in advanced therapeutic applications. Our expertise spans multiple serotypes and constructs, enabling flexibility for ophthalmic, neurological, and systemic delivery programs. By combining scientific insight with cutting-edge manufacturing technologies, we help innovators translate complex therapies into clinical and commercial reality.

3PBIOVIAN operates as a fully certified cGMP AAV manufacturing CDMO, adhering to international guidelines and audit-ready standards. Our facilities are designed for biosafety, sterility, and scalability, with rigorous in-process controls ensuring reproducibility and batch integrity. Every vector produced undergoes comprehensive release testing and documentation aligned with EMA and FDA expectations.

Regulatory compliance is at the core of our operations. Our AAV manufacturing CDMO teams maintain validated processes, controlled environments, and complete traceability from plasmid preparation to final fill-finish. We offer detailed regulatory support, CMC documentation, and QA/QC oversight to facilitate smooth submissions and inspections at every clinical stage.

As an experienced AAV GMP manufacturing company, 3PBIOVIAN ensures that each production campaign delivers exceptional quality and consistency. Our scalable bioreactor systems, purification strategies, and analytics guarantee optimal vector yield, potency, and purity. Clients trust us for our proven ability to meet deadlines, uphold GMP standards, and adapt rapidly to evolving project needs.